These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25226813)

  • 1. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.
    Calles A; Kwiatkowski N; Cammarata BK; Ercan D; Gray NS; Jänne PA
    Mol Oncol; 2015 Jan; 9(1):260-9. PubMed ID: 25226813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
    Katayama R; Aoyama A; Yamori T; Qi J; Oh-hara T; Song Y; Engelman JA; Fujita N
    Cancer Res; 2013 May; 73(10):3087-96. PubMed ID: 23598276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
    Sugano T; Seike M; Noro R; Soeno C; Chiba M; Zou F; Nakamichi S; Nishijima N; Matsumoto M; Miyanaga A; Kubota K; Gemma A
    Mol Cancer Ther; 2015 Nov; 14(11):2433-40. PubMed ID: 26351321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
    J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.
    Wei K; Li M; Zöller M; Wang M; Mehrabi A; Hoffmann K
    Cell Death Dis; 2019 Mar; 10(3):231. PubMed ID: 30850583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
    Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
    J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.
    Basilico C; Pennacchietti S; Vigna E; Chiriaco C; Arena S; Bardelli A; Valdembri D; Serini G; Michieli P
    Clin Cancer Res; 2013 May; 19(9):2381-92. PubMed ID: 23532890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
    Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-target effects of c-MET inhibitors on thyroid cancer cells.
    Zhou Y; Zhao C; Gery S; Braunstein GD; Okamoto R; Alvarez R; Miles SA; Doan NB; Said JW; Gu J; Phillip Koeffler H
    Mol Cancer Ther; 2014 Jan; 13(1):134-43. PubMed ID: 24170771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEK inhibitors against MET-amplified non-small cell lung cancer.
    Chiba M; Togashi Y; Tomida S; Mizuuchi H; Nakamura Y; Banno E; Hayashi H; Terashima M; De Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
    Int J Oncol; 2016 Dec; 49(6):2236-2244. PubMed ID: 27748834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells.
    Remsing Rix LL; Kuenzi BM; Luo Y; Remily-Wood E; Kinose F; Wright G; Li J; Koomen JM; Haura EB; Lawrence HR; Rix U
    ACS Chem Biol; 2014 Feb; 9(2):353-8. PubMed ID: 24215125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.
    Lu S; Török HP; Gallmeier E; Kolligs FT; Rizzani A; Arena S; Göke B; Gerbes AL; De Toni EN
    Oncotarget; 2015 Sep; 6(26):22167-78. PubMed ID: 26259250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer.
    Thu YM; Suzawa K; Tomida S; Ochi K; Tsudaka S; Takatsu F; Date K; Matsuda N; Iwata K; Nakata K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Toyooka S
    PLoS One; 2024; 19(5):e0300644. PubMed ID: 38758826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
    Nanjo S; Yamada T; Nishihara H; Takeuchi S; Sano T; Nakagawa T; Ishikawa D; Zhao L; Ebi H; Yasumoto K; Matsumoto K; Yano S
    PLoS One; 2013; 8(12):e84700. PubMed ID: 24386407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
    Yasuda H; de Figueiredo-Pontes LL; Kobayashi S; Costa DB
    J Thorac Oncol; 2012 Jul; 7(7):1086-90. PubMed ID: 22617245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
    Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
    Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
    Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition.
    Reuther C; Heinzle V; Spampatti M; Vlotides G; de Toni E; Spöttl G; Maurer J; Nölting S; Göke B; Auernhammer CJ
    Neuroendocrinology; 2016; 103(3-4):383-401. PubMed ID: 26338447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.